Regeneron Pharmaceuticals, Inc.

Progenics Pharmaceuticals, Inc.

Psma Development Company, LLC

Other

Amgen Fremont Inc.

Regeneran Pharmaceuticals, Inc.

Facet Biotech Corporation

Cytodyn Inc.

Aaron Diamond Aids Research Centre (adarc)

Pdl Biopharma, Inc.

Aaron Diamond Aids Research Centre

Arogenics Pharmaceuticals, Inc.

Cornell Research Foundation Inc.

Abbott Biotherapeutics Corp.

William C Olson

Paul J Maddon

Gavin Thurston

Christos Kyratsous

Dangshe Ma

Andrew J Murphy

Neil E Stahl

Peter W Mason

Amy Han

Norbert Schuelke

Robert Babb

Marcus Kelly

George D Yancopoulos

Gang Chen

Tammy T Huang

John S Moore

Frank Delfino

Alina Baum

Wen-Yi Lee

Gerald P Donovan

Cindy Gerson

Johanna Hansen

Marine Malbec

Richard Tavare

Elena Garnova

Naoya Tsurushita

Jessica Kirshner

Graham P Allaway

Lisa A Purcell

Virginia M Litwin

Sokol Haxhinasto

Matthew Sleeman

Jason Gardner

James M Binley

Jonathan Viau

Jesper Gromada

Thomas Nittoli

Ying Hu

Douglas MacDonald

Paul Robert Hinton

Carmelo Romano

Matthew Franklin

Adrianna Latuszek

Alida Coppi

Kevin A Bray

Jason T Giurleo

Robert J Israel

Larry L Green

Jaspal Singh Kang

Daniel C Pevear

Jeanette L Fairhurst

Elena Burova

Ella Ioffe

Viktoria Gusarova

Dimitris Skokos

Aynur Hermann

Yashu Liu

Drew Dudgeon

Yu Huang

Bei Wang

Tatjana Dragic

Rosalynn Molden

Nicholas J Papadopoulos

Maximiliano Vasquez

Joel H Martin

Peter Senter

Shankar Kumar

Brian E Toki

Jee Hwan Kim

Christopher Daly

Haruka Okamoto

Panayiotis Stevis

Sarah Jane Hatsell

Julian Andreev

Min Lu

Maximillano Vasquez

Jose D Murga

Albert Cupo

Anna Zumsteg

Stephen Morris

Kirsten Nagashima

Brian Kennedy

Yun Kang

Andre J Marozsan

Antu K Dey

Sai Prasad N Iyer

Yun (Kenneth) Kang

Michael Franti

David Esopi

Jorge Haller

Christopher D'Souza

Harvey Chin

Heinrich Emil Lob

Bojie Zhang

Andres Perez Bay

Kei Saotome

Wen-yi Lee

Vincent Dipippo

Svetlana O Doronina

Provided herein are monoclonal antibodies that bind to the transmembrane serine protease 6 (TMPRSS6) protein, and methods of use thereof. In various embodiments of the disclosure, the antibodies are fully human antibodies that bind to TMPRSS6. In some embodiments, the antibodies disclosed herein are useful in a method for treating or preventing a disease, disorder or condition associated with TMPRSS6 in humans.

Anti-TMPRSS6 antibodies and uses thereof

Described herein are protein steroid conjugates that are useful, for example, for the target-specific delivery of glucocorticoids (GCs) to cells.

Steroids and protein-conjugates thereof

Provided herein are compounds, compositions and methods for the treatment of diseases and disorders associated with the liver X receptor, including bis-octahydrophenanthrene carboxamides and protein (e.g., antibody) drug conjugates thereof.

Bis-octahydrophenanthrene carboxamides and protein conjugates thereof

Provided herein are antibodies, and antigen-binding fragments thereof that specifically bind glucocorticoid-induced tumor necrosis factor receptor (GITR), compositions comprising the antibodies or antigen-binding fragments thereof, and methods of using the same, including, e.g., methods of treatment using the same.

Therapeutic uses of anti-GITR antibodies

Described herein are protein-drug conjugates and compositions thereof that are useful, for example, for targeting glucagon-like peptide 1 receptor (GLP1R). In certain embodiments, provided are peptidomimetic payloads and linker-payloads and methods of making same. More specifically, GLP1 peptidomimetics, antibody-drug conjugates, and compositions which comprise anti-GLP1R antibodies and GLP1 peptidomimetic payloads and methods of treating GLP1R-associated conditions are provided.

Antibody-drug conjugates comprising GLP1 peptidomimetics and uses thereof

The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).

Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments

Provided herein are compounds or payloads, linker-payloads, antibody-drug conjugates, and compositions, and methods for the treatment of diseases and disorders associated with the liver X receptor, including bis-octahydrophenanthrene carboxamides and protein (e.g., antibody) drug conjugates thereof.

Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as LXR agonists

The present invention provides monoclonal antibodies, or antigen-binding fragments thereof, that bind to Ebola virus glycoproteins, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for inhibiting or neutralizing Ebola virus activity, thus providing a means of treating or preventing Ebola virus infection in humans. In some embodiments, the invention provides for use of one or more antibodies that bind to the Ebola virus for preventing viral attachment and/or entry into host cells. The antibodies of the invention may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines.

Human antibodies to ebola virus glycoprotein

Provided herein are compounds, compositions, and methods for the treatment of diseases and disorders associated with cancer, including tubulysins and protein (e.g., antibody) drug conjugates thereof.

Tubulysins and protein-tubulysin conjugates

The present invention provides antigen-binding proteins that specifically bind to an HLA-displayed human papillomavirus (HPV) peptide, and therapeutic and diagnostic methods of using those binding proteins.

Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof

Vascular endothelial growth factor (VEGF) traps and VEGF mini-traps that include VEGF receptor Ig-like domains, fused to a multimerizing component, are disclosed. The VEGF traps and VEGF mini-traps bind to VEGF and block its interaction with the VEGF receptor. Such molecules are useful for treating angiogenic eye disorders (e.g., age-related macular degeneration), cancer and for other undesired angiogenesis.

VEGF traps and mini-traps and methods for treating ocular disorders and cancer

Anti-CD8 antibodies, radiolabeled anti-CD8 antibodies, fluorescently labeled anti-CD8 antibodies and their use in imaging are provided herein. Included are methods of detecting the presence of CD8 proteins in a subject or sample.

Anti-CD8 antibodies and uses thereof

The present invention provides antibodies and antigen-binding fragments (e.g., human antibodies) that bind specifically to human Interleukin-36 receptor (IL36R). Methods for treating or preventing diseases mediated by IL36R (e.g., skin or colon inflammatory conditions such as palmo-plantar pustular psoriasis, palmoplantar pustulosis, generalized pustular psoriasis, ulcerative colitis or IBD) using the antibodies and fragments are also provided along with methods of making the antibodies and fragments.

Anti-IL36R antibodies

Radiolabeled anti-PD-L1 antibodies and their use in immuno-PET imaging are provided herein. Included are methods of detecting the presence of PD-L1 proteins in a patient or sample.

Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging

The present invention provides antibodies that bind to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to CTLA-4. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing CTLA-4 activity, thus providing a means of activating T-cells and/or for treating a disease or disorder such as cancer or viral infection.

Anti-CTLA-4 antibodies and uses thereof

Growing community of inventors

Ossining, NY, United States of America

William C Olson